CEO: Magnus Persson
From idea to business-for public health and welfare. A large part of the innovation system at Karolinska Institutet is managed by Karolinska Institutet Holding AB
Karolinska Institutet places great value on a dynamic interaction between the academic and the commercial sectors – for mutual benefits and general improvement for the whole society.
To enable professional evaluation, development and commercialisation of interesting innovations in Life Science and Medical Technology an overall innovationsystem has been created – KI Innovation.
This unique system develops research ideas from both Swedish and other Nordic universities.
Some of the main tasks for KI Holding is to manage stocks in research-and development companies, establish joint ownership in promising enterprises, offer good infrastructure for newly started companies and to provide administrative, legal and financial services for around 45 companies.
Karolinska Institutet Holding AB, creates the possibility for KI to act commercially. This means that KI Holding can take risks and also is allowed to make profits – as opposed to state-owned Karolinska Institutet.
KI Holding operates mainly through the wholly owned subsidiary companies: Karolinska Instututet Housing AB, Karolinska Institutet Innovations AB, Karolinska Institutet Science Park AB and Karolinska Institutet University Press AB
KI Holding owns 16 percent of the shares in the investment company Karolinska Development AB, which has a portfolio of around 40 companies in the Life Science sector.
KI Holding also owns 25 percent of the shares in Biocelex Oy, an innovation- and business development company based in Turku, Finland.